We have constructed a dam mutant of Yersinia pestis GB. In BALB/c mice inoculated subcutaneously, the median lethal dose of the mutant was at least 2000-fold higher than the wild type. Mice inoculated with sub-lethal doses of the mutant were protected against a subsequent challenge with virulent Y. pestis. The effect of dam inactivation on gene expression was examined using a DNA microarray, which revealed increased expression of a number of genes associated with the SOS response. These results confirm the key role of Dam in the regulation of virulence, and its potential role as a target for the generation of attenuated strains of pathogenic bacteria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.femsle.2005.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differences in Gender and Overall Survival for Temperature-Sensitive TP53 Mutations in Gastroesophageal Cancer.
Medicina (Kaunas)
November 2024
Department of GI Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
: Temperature-sensitive (TS) mutants of TP53 are thermally unstable, unfolded, and inactive at body temperature but can be refolded and reactivated at sub-physiological temperatures. TS TP53 may be amenable for functional rescue by hypothermia or structure-stabilizing drugs, and may retain low-level transcriptional activity at 37 °C. TP53 mutations are observed in 47% of all esophageal cancers (ECs) and 25% to 40% of gastric cancers (GCs).
View Article and Find Full Text PDFComparative analysis of biofilm structures in Salmonella Typhimurium DMC4 strain and its dam and seqA gene mutants using Fourier transform infrared spectroscopy (FT-IR) and Raman spectroscopy methods.
Braz J Microbiol
November 2024
Department of Biology, Ankara University, Ankara, Turkey.
It is well-established that the dam and seqA genes act in the biofilm production in Salmonella. However, the molecular basis underlying this activity remains unexplored. This study aims to address this gap in the literature.
View Article and Find Full Text PDFA novel ITGB8 transcript variant sustains ovarian cancer cell survival through genomic instability and altered ploidy on a mutant p53 background.
J Ovarian Res
November 2024
National Centre for Cell Science, Pune, 411007, India.
Background: Transcript variants and protein isoforms are central to unique tissue functions and maintenance of homeostasis, in addition to being associated with aberrant states such as cancer, where their crosstalk with the mutated tumor suppressor p53 may contribute to genomic instability and chromosomal rearrangements. We previously identified several novel splice variants in ovarian cancer RNA-sequencing datasets; herein, we aimed to elucidate the biological effects of the Integrin Subunit Beta 8 variant (termed pITGB8-205).
Methods: Resolution of the full-length sequence of pITGB8-205 through rapid amplification of cDNA ends (RACE-PCR).
Relationship of Typhimurium 14028 strain and its and mutants with gut microbiota dysbiosis in rats.
J Med Microbiol
September 2024
Department of Biology, Ankara University, Yenimahalle, 06100, Ankara, Turkey.
Article Synopsis
- Dysbiosis in gut microbiota, linked to infections, may be significantly influenced by the Typhimurium 14028 WT strain.
- The study investigates how this strain affects rat gut microbiota and the roles of specific genes in inducing dysbiosis.
- Results indicate that infection with Typhimurium alters microbiota composition, reduces diversity and richness, and promotes opportunistic pathogens.
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.
Nat Med
November 2024
Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), University of Vic-Central University of Catalonia, Barcelona, Spain.
The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC, providing the basis for the approval of the Enco+Cetux regimen in the United States and the European Union. A greater understanding of biomarkers predictive of response to Enco+Cetux±Bini treatment is of clinical relevance. In this prespecified, exploratory biomarker analysis of the BEACON CRC study, we characterize genomic and transcriptomic correlates of clinical outcomes and acquired resistance mechanisms through integrated clinical and molecular analysis, including whole-exome and -transcriptome tissue sequencing and circulating tumor DNA genomic profiling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!